미국 · 보도자료 · VBIO · 2026-10-05 12:30
토마스 젠슨 신임 이사회 의장 선임, 엔톨리모드 개발 탄력
Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today outlined the perspectives of its new Board Chair, Thomas H. Jensen, on advancing Entolimod. Entolimod is an investigational Toll-like receptor 5 (TLR5) agonist being developed as a potential
